GME - Key Persons
Endocrinologist Aaron Hsueh discovers obestatin, a hormone that supresses appetite and may lead to treatments for obesity.
Job Titles:
- Postdoctoral Research Mentor
Job Titles:
- Student, Expected Graduation Spring 2024 Ph.D. Student in Stem Cell Biology and Regenerative Medicine, Admitted Autumn 2019 MSTP Student
Job Titles:
- Director, Graduate Medical Education
Pharmacologist Avram Goldstein discovers a chemical in the human brain that could lead to the development of powerful painkillers with fewer undesirable side effects.
Job Titles:
- Clinical Professor, Pediatrics - Endocrinology and Diabetes
Job Titles:
- PRESIDENT & CEO / STANFORD HEALTH CARE
Job Titles:
- Clinical Assistant Professor, Medicine - Hematology
Job Titles:
- Dean
- Head
- Physician
- Scientist
- Surgeon
- Professor for the Dean
- Vice Dean Linda M. Boxer
Dean Minor is a leading physician, basic scientist and educator.
Lloyd B. Minor, MD, is a scientist, surgeon, and academic leader. He is the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine, a position he has held since December 2012. He also is a professor of Otolaryngology-Head and Neck Surgery and a professor of Bioengineering and of Neurobiology, by courtesy, at Stanford University.
As dean, Dr. Minor plays an integral role in setting strategy for the clinical enterprise of Stanford Medicine, an academic medical center that includes the Stanford University School of Medicine, Stanford Health Care, and Stanford Medicine Children's Health. With his leadership, Stanford Medicine leads the biomedical revolution in Precision Health. His book, "Discovering Precision Health," describes this shift to more preventive, personalized health care and highlights how biomedical advances are dramatically improving our ability to treat and cure complex diseases. In 2021, Dr. Minor articulated and began realizing a bold vision to transform the future of life sciences at Stanford University and beyond - a multi-decade journey enabled by Precision Health.
Before Stanford, Dr. Minor was provost and senior vice president for academic affairs of Johns Hopkins University. Prior to this appointment in 2009, Dr. Minor served as the Andelot Professor and director (chair) of the Department of Otolaryngology-Head and Neck Surgery in the Johns Hopkins University School of Medicine and otolaryngologist-in-chief of The Johns Hopkins Hospital.
With more than 160 published articles and chapters, Dr. Minor is an expert in balance and inner ear disorders perhaps best known for discovering superior canal dehiscence syndrome, a debilitating disorder characterized by sound- or pressure-induced dizziness. He subsequently developed a surgical procedure that corrects the problem and alleviates symptoms.
In 2012, Dr. Minor was elected to the National Academy of Medicine.
Carl and Elizabeth Naumann Professor for the Dean of the School of Medicine, Professor of Otolaryngology - Head & Neck Surgery, and by courtesy, of Neurobiology & Bioengineering
Lloyd B. Minor, MD, is a scientist, surgeon, and academic leader. He is the Carl and Elizabeth Naumann Dean of the Stanford University School of Medicine, a position he has held since December 2012. He also is a professor of Otolaryngology-Head and Neck Surgery and a professor of Bioengineering and of Neurobiology, by courtesy, at Stanford University.
As dean, Dr. Minor plays an integral role in setting strategy for the clinical enterprise of Stanford Medicine, an academic medical center that includes the Stanford University School of Medicine, Stanford Health Care, and Stanford Medicine Children's Health. He oversees the quality of Stanford Medicine's physicians on the faculty and in the growing clinical networks and physician practices.
At the beginning of the COVID-19 pandemic, Dr. Minor reacted quickly to implement protocols to ensure the safety of patients and of the Stanford Medicine community. He emphasized open communication, transparency, and accountability as he and the leadership team responded to the unprecedented challenges that affected every facet of the enterprise's activities.
With Dr. Minor's leadership, Stanford Medicine is leading the biomedical revolution through Precision Health. Empowering people to lead healthy lives, Precision Health is a fundamental shift to more proactive and personalized health care that predicts and prevents disease before it strikes and cures it decisively if it does. His book, "Discovering Precision Health: Predict, Prevent, and Cure to Advance Health and Well-Being," highlights how biomedical advances are dramatically improving our ability to treat and cure complex diseases.
Dr. Minor also spearheaded the creation of an Integrated Strategic Plan (ISP) that reaffirms Stanford Medicine's Precision Health vision while articulating a new commitment to be Human Centered and Discovery Led. An unprecedented roadmap, the ISP aligns Stanford Medicine's three entities, informs how each will develop strategies and make decisions, and is activating more than two dozen high-impact initiatives across Stanford Medicine.
In 2021, Dr. Minor articulated and began realizing a bold vision for transforming the future of life sciences at Stanford University, in the Bay Area, and beyond. This multi-decade journey will leverage the region's unique strengths in information sciences, technology, and biology and biomedicine to establish a biomedical innovation hub that through collaboration enhances fundamental understanding of biology and translates promising discoveries into transformative leaps that promote human and planetary well-being.
Dr. Minor has long provided significant support for basic science research and for clinical and translational research at Stanford. Through bold initiatives in medical education and increased support for MD and PhD students, Dr. Minor is committed to inspiring and training future leaders. He also has increased student financial aid and expanded faculty leadership opportunities.
Among other accomplishments Dr. Minor has led the development and implementation of an innovative model for cancer research and patient care delivery at Stanford Medicine and has launched an initiative in biomedical data science to harness the power of big data and create a learning health care system.
Before Stanford, Dr. Minor was provost and senior vice president for academic affairs of The Johns Hopkins University. As provost, Dr. Minor launched many university-wide initiatives such as the Gateway Sciences Initiative to support pedagogical innovation, and the Doctor of Philosophy Board to promote excellence in PhD education. He worked with others around the university and health system to coordinate the Individualized Health Initiative, which aimed to use genetic information to transform health care.
Prior to his appointment as provost in 2009, Dr. Minor was the Andelot Professor and director (chair) of the Department of Otolaryngology-Head and Neck Surgery in the Johns Hopkins University School of Medicine and otolaryngologist-in-chief of The Johns Hopkins Hospital. During his six-year tenure, he expanded annual research funding by more than half and increased clinical activity by more than 30 percent, while strengthening teaching efforts and student training.
With more than 160 published articles and chapters, Dr. Minor is an expert in balance and inner ear disorders. Through neurophysiological investigations of eye movements and neuronal pathways, his work has identified adaptive mechanisms responsible for compensation to vestibular injury in a model system for studies of motor learning (the vestibulo-ocular reflex). The synergies between this basic research and clinical studies have led to improved methods for the diagnosis and treatment of balance disorders. In recognition of his work in refining a treatment for Ménière's disease, Dr. Minor received the Prosper Ménière Society's gold medal in 2010.
In the medical community, Dr. Minor is perhaps best known for his discovery of superior canal dehiscence syndrome, a debilitating disorder characterized by sound- or pressure-induced dizziness. In 1998, Dr. Minor and colleagues published a description of the clinical manifestations of the syndrome and related its cause to an opening (dehiscence) in the bone covering the superior canal. He subsequently developed a surgical procedure that corrects the problem and alleviates symptoms.
Dr. Minor received his bachelor's and medical degrees from Brown University. He trained at Duke University Medical Center and the University of Chicago Medical Center and completed a research fellowship at the University of Chicago and a clinical fellowship at The Otology Group and The EAR Foundation in Nashville, Tennessee.
In 2012, Dr. Minor was elected to the National Academy of Medicine.
As part of the Stanford Executive Briefing series, Minor shares his thoughts on authentic leadership and offers five leadership principles.
Job Titles:
- Professor of Medicine ( Oncology ) and of Pathology / Research
Job Titles:
- Professor of Medicine ( Oncology ), Emeritus / Research
Job Titles:
- Chief Medical Officer
- Chief Medical Officer, Stanford Health Care
- Clinical Professor, Medicine
- Professor
Dr. Niraj Sehgal is a Professor of Medicine, Chief Medical Officer for Stanford Healthcare, and Senior Associate Dean for Clinical Affairs in the School of Medicine. His clinical practice is focused in hospital medicine, while his academic career has been focused on leading initiatives that foster interprofessional teamwork/communication, promote a culture for learning/improvement, and cultivate workforce development as key strategies to deliver outstanding patient outcomes. He's also worked to establish and influence the role of quality and safety as an academic endeavor.
Prior to returning to Stanford in September 2020, Niraj spent 16 years at UCSF where he held several leadership roles that included directing a medical service, leading a faculty development program, directing physician leadership programs, and serving as the first Associate Chair for Quality & Safety within an academic department. His final role was as UCSF Health's inaugural Chief Quality Officer where he worked to further align and improve the care delivery system. Niraj is also a passionate teacher and mentor who was inducted into UCSF's Academy of Medical Educators in 2009.
Job Titles:
- Associate Professor of Radiation Oncology ( Radiation Physics ) and, by Courtesy, of Radiology ( Molecular Imaging Program at Stanford )
Job Titles:
- Program Manager / Education Specialist
Sleep researcher Emmanuel Mignot identifies the defective gene that causes narcolepsy, a disabling sleep disorder affecting humans and animals.
Pathologist Eugene Butcher discovers a receptor that guides white blood cells into the peripheral lymph nodes.
Job Titles:
- Associate Professor of Surgery ( General Surgery )
Pathologist Gerald Crabtree develops techniques that allow scientists to toggle genes on and off in animal models.
Job Titles:
- Professor of Neurosurgery and, by Courtesy, of Neurology and of Otolaryngology - Head & Neck Surgery ( OHNS )
High Grade Gliomas, including anaplastic astrocytomas, anaplastic oligodendrogliomas and glioblastomas (GBM), are the most common and most aggressive primary brain tumors. Prognosis for patients with high-grade gliomas remains poor. The estimated median survival for patients with GBM is between 12 to 18 months. Recurrence after initial therapy with temozolomide and radiation is nearly universal. Since May 2009, the majority of patients in the US with an initial recurrence of high-grade glioma receive bevacizumab, a monoclonal antibody against vascular endothelial growth factor (VEGF), which is thought to prevent angiogenesis in these highly vascular tumors. BEV has response rates from 32-62% and has improved overall median survival in patients with recurrent high-grade gliomas1. However, the response is short lived, and nearly 100% of patients eventually progress despite bevacizumab. No chemotherapeutic agent administered following progression through bevacizumab has made a significant impact on survival. Patients progress to death within 1-5 months after resistance develops. Therefore, patients with high-grade gliomas who have progressed through bevacizumab represent a population in dire need of a feasible and tolerable treatment. NKTR-102 is a topoisomerase I inhibitor polymer conjugate that was engineered by attaching irinotecan molecules to a polyethylene glycol (PEG) polymer using a biodegradable linker. Irinotecan released from NKTR-102 following administration is further metabolized to the active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN38), that causes DNA damage through inhibition of topoisomerase. The goal in designing NKTR-102 was to attenuate or eliminate some of the limiting side effects of irinotecan while improving efficacy by modifying the distribution of the agent within the body. The size and structure of NKTR-102 results in marked alteration in pharmacokinetic (PK) profile for the SN38 derived from NKTR-102 compared to that following irinotecan: the maximal plasma concentration (Cmax) is reduced 5- to 10-fold and the half-life (t1/2 ) of SN38 is increased from 2 days to approximately 50 days. This altered profile leads to constant exposure of the tumor to the active drug. In addition, the large NKTR-102 molecule does not freely pass out of intact vasculature, which may account for relatively higher concentrations of the compound and the active metabolites in tumor tissues in in vivo models, where the local vasculature may be relatively more permeable. A 145 mg/m2 dose of NKTR-102, the dose intended for use in this phase II clinical trial (and being used in the phase III clinical program), results in approximately the same plasma exposure to SN38 as a 350 mg/m2 dose of irinotecan, but exposure is protracted, resulting in continuous exposure between dosing cycles and lower Cmax. NKTR-102 was therefore developed as a new chemotherapeutic agent that may improve the clinical outcomes of patients.
Job Titles:
- Clinical Associate Professor, Emergency Medicine
Immunologist Hugh McDevitt discovers regulatory genes believed to control the body's reponses to foreign proteins, which suggests that people may have predictable susceptibility to certain diseases.
Dr. Gibbs is a board-certified radiation oncologist who specializes in the treatment of CNS tumors. Her research focuses on developing new radiation techniques to manage brain and spinal tumors in adults and children. Dr. Gibbs has gained worldwide acclaim for her expertise in Cyberknife robotic radiosurgery.
Pathologist Irving Weissman isolates a rare mouse cell, known as the hematopoetic stem cell, which gives rise to all the cells of the blood and immune systems.
Pathologist Irving Weissman identifies the stem cell that gives rise to bladder cancer, and also shows how the cell uses the "don't-eat-me" signal, a molecule known as CD47, to evade the body's defenses.
Pathologist Irving Weissman shows that a single antibody, which counters the effect of the CD47 molecule, shrinks a variety of human tumors transplanted into mice.
Job Titles:
- Sam Willson Professor and Professor of Radiation Oncology ( Radiation Therapy )
- Sam Willson Professor, Professor of Radiation Oncology, Emeritus
Job Titles:
- Professor of Medicine ( Oncology ) and of Genetics and, by Courtesy, of Pediatrics
Job Titles:
- Senior Program Manager / Education Specialist
Job Titles:
- Professor, Professor of Statistics and of Biomedical Data Sciences
Job Titles:
- Peter Wood Lead the First Large Clinical Investigation That Shows Lowering Cholesterol Levels Prevents Heart Disease
John Farquhar and Peter Wood lead the first large clinical investigation that shows lowering cholesterol levels prevents heart disease.
Job Titles:
- the Dorothy and Thye King Chan Professor in Neurosurgery, Emeritus / Research
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)
Job Titles:
- Professor of Radiation Oncology ( Radiation Therapy )
Job Titles:
- Professor of Medicine ( Oncology )
Job Titles:
- Associate Dean for Graduate Medical Education / Chair, Graduate Medical Education Committee ( GMEC )
- Professor of Neurosurgery and of Medicine ( Endocrinology )
Laurence Katznelson, MD received his medical degree from the University of California, Los Angeles and performed his internship and residency in Internal Medicine at the Hospital of the University of Pennsylvania, Philadelphia. He then performed a fellowship in Endocrinology and Metabolism at the Massachusetts General Hospital, Boston. Dr. Katznelson is a Professor of Neurosurgery and Medicine (Endocrinology)at Stanford University School of Medicine. At Stanford University, he is the Associate Dean of Graduate Medical Education and the Chair of the GME Committee. Dr. Katznelson is the Medical Director of the Pituitary Center at Stanford Hospital and Clinics. He is the medical director of the Pituitary Stanford, Stanford HealthCare. In endocrinology, Dr. Katznelson has a long standing clinical and research interest in the pathophysiology and treatment of pituitary disease.
Job Titles:
- Professor of Neurology and, by Courtesy, of Neurosurgery
Stanford is currently not accepting patients for this trial. For more information, please contact Cathy Kahn Recht, 650725863.
Pathologist Marius Wernig turns mouse skin cells into cells that insulate neurons with the application of just three genes.
Immunologist Mark Davis characterizes the T-cell receptor, believed to regulate the body's response to infectious agents and cancerous diseases.
Mary Gohlke receives the world's first combined heart and lung transplant in a landmark operation led by surgeon Bruce Reitz.
Job Titles:
- Executive Assistant to Dean Lloyd Minor, MD, Office of the Dean, Chief of Staff
Job Titles:
- Professor in the School of Medicine
Job Titles:
- Professor of Neurosurgery and, by Courtesy, of Neurology
Job Titles:
- Associate Professor of Medicine ( Oncology )
- Associate Professor of Medicine in the Division
Dr. Melinda Telli is an Associate Professor of Medicine in the Division of Medical Oncology at Stanford University School of Medicine, Director of the Breast Cancer Program at the Stanford Cancer Institute and Associate Director of the Stanford Women's Cancer Center. Dr. Telli's research focuses on the development of novel therapies for the treatment of triple-negative and hereditary cancer. Her work has focused on the validation of homologous recombination deficiency biomarkers to help identify patients with sporadic triple-negative breast cancer that may specifically derive benefit from DNA repair defect-targeted therapies. In addition to her involvement in the clinical development of PARP inhibitors for BRCA1 and BRCA2 mutation-associated cancers, she has also explored the use of ‘beyond BRCA' DNA repair gene mutations as potential biomarkers to select patients for PARP inhibitor therapy in the advanced disease setting.
Dr. Telli received her undergraduate degree from the University of Pennsylvania Magna Cum Laude and medical degree from George Washington University with Distinction. She completed internship and residency in Internal Medicine at Stanford University, and then stayed at Stanford to pursue fellowship training in Medical Oncology. She has served on numerous American Society of Clinical Oncology Committees and currently serves as a Komen Scholar, member of the National Comprehensive Cancer Network Breast Cancer Guideline Panel and member of the Journal of Clinical Oncology Editorial Board. Dr. Telli is the recipient of a Susan G. Komen for the Cure Translational Postdoctoral Fellowship Award (2008), American Society of Clinical Oncology Young Investigator Award (2009), Susan G. Komen for the Cure Leadership Award (2015 and 2018), Triple Negative Breast Cancer Foundation Hero Award (2018) and Komen SF Bay Area Visionary Award (2019). She has garnered multiple teaching accolades and is a repeat recipient of the Stanford Division of Oncology Teaching Award.
Job Titles:
- Stanford Medicine Discovery Professor, Professor of Epidemiology and Population Health and, by Courtesy, of Pediatrics
Job Titles:
- Professor of Radiology ( Nuclear Medicine ), Emeritus
Job Titles:
- Senior Associate Dean for Medical Education, George DeForest Barnett Founders Professor of Medicine and Professor ( Teaching ) of Medicine ( Endocrinology )
Job Titles:
- Associate Professor of Medicine ( Biomedical Informatics ) and of Biomedical Data Science / Research
Job Titles:
- Beirne Family Professor of Pediatric Neuro - Oncology, Professor of Pediatrics and, by Courtesy, of Neurosurgery and of Epidemiology and Population Health
Job Titles:
- Clinical Instructor, Medicine - Oncology
Job Titles:
- Member of the Education Team
Job Titles:
- Peter Wood Lead the First Large Clinical Investigation That Shows Lowering Cholesterol Levels Prevents Heart Disease
Job Titles:
- Clinical Professor, Anesthesiology, Perioperative and Pain Medicine
Job Titles:
- Professor of Medicine ( Oncology and General Internal Medicine / Medical Informatics ) at the Stanford University Medical Center, Emeritus / Research
Job Titles:
- Program Project Coordinator
Surgeon Roy Cohn leads the first human kidney transplant operation on the West Coast.
Radiologist Sanjiv Gambhir develops a new type of imaging system that can illuminate tumors in living subjects with a precision of nearly one-trillionth of a meter
Job Titles:
- Clinical Associate Professor, Neurosurgery
Job Titles:
- Head of the the Stanford Neuromolecular Innovation Program
Dr. Chang is also the head of the The Stanford Neuromolecular Innovation Program with the goal of developing new technologies to improve the diagnosis and treatment of patients affected by neurological conditions.
Job Titles:
- Professor of Radiation Oncology ( Radiation Therapy ), Emeritus
Job Titles:
- Program Manager / Education Specialist
Pediatrician Thomas Robinson finds that children who curtailed their television time gained significantly less body fat than those who didn't .
Researcher William Haskell shows that intensive lifestyle changes and prevention/treatment programs can reduce cardiac events and slow the progression of atherosclerosis in coronary arteries.
Researcher William S. Robinson isolates the genetic blueprint of a virus that causes hepatitis B and a common form of liver cancer.